Current state of prostate cancer treatment and future strategies

Prostate cancer (PCa) is the most common malignancy in men. It forms heterogeneous PCa masses with lining epithelial cells that require androgen signaling, and heterogeneous PCa masses can metastasize to lymph nodes and bone, making early diagnosis and treatment critical. PCa treatments include chemical castration, surgical resection, chemotherapy, hormonal changes, and androgen deprivation therapy. Diagnosis begins with a digital rectal exam (DRE) or prostate-specific antigen, and is often associated with a negative prognosis and pain. Furthermore, malignancy metastasizes or recurs to the bone. It is vital to develop personalized treatment based on the understanding of cancer pathophysiology. PCa is an aggressive multifactorial disease being focused in men’s health research. PCa handling is crucial in men’s survival. It is constantly studied for diagnosis, prevention and treatment. This article reviews it from therapeutic perspective. It thus summarizes current and emerging therapeutic strategies and biomarkers for PCa.

Prostate cancer; Treatment strategies; Target agent; Biomarker; Men’s health

[1] Sun DQ, Lei L, Cai Y, Li H, Cao MM, He SY, et al. Research advances in the relationship of dietary factors and prostate cancer risk. Chinese Journal of Oncology. 2021; 43: 443–448. (In Chinese)

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[3] Rawla P. Epidemiology of prostate cancer. World Journal of Clinical Oncology. 2019; 10: 63–89.

[4] Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nature Reviews Clinical Oncology. 2014; 11: 365–376.

[5] Skvortsov S, Skvortsova II, Tang DG, Dubrovska A. Concise review: prostate cancer stem cells: current understanding. Stem Cells. 2018; 36: 1457–1474.

[6] Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, et al. A healthy lifestyle in men at increased genetic risk for prostate cancer. European Urology. 2023; 83: 343–351.

[7] Berenguer CV, Pereira F, Câmara JS, Pereira JAM. Underlying features of prostate cancer—statistics, risk factors, and emerging methods for its diagnosis. Current Oncology. 2023; 30: 2300–2321.

[8] Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. European Urology. 2020; 77: 38–52.

[9] Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, et al. Epidemiology, staging and management of prostate cancer. Medical Sciences. 2020; 8: 28.

[10] Pinsky PF, Parnes H. Screening for prostate cancer. New England Journal of Medicine. 2023; 388: 1405–1414.

[11] Chen S. Huang V, Xu X, Livingstone J, Soares F, Jeon J, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019; 176: 831–843.e22.

[12] Mei W, Lin X, Kapoor A, Gu Y, Zhao K, Tang D. The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis. Cancers. 2019; 11: 434.

[13] Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent MÉ. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015; 15: 913.

[14] Bax C, Taverna G, Eusebio L, Sironi S, Grizzi F, Guazzoni G, et al. Innovative diagnostic methods for early prostate cancer detection through urine analysis: a review. Cancers. 2018; 10: 123.

[15] Kasivisvanathan V, Rannikko A, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. The New England Journal of Medicine. 2018; 378: 1767–1777.

[16] Barani M, Sabir F, Rahdar A, Arshad R, Kyzas GZ. Nanotreatment and nanodiagnosis of prostate cancer: recent updates. Nanomaterials. 2020; 10: 1696.

[17] McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World Journal of Gastroenterology. 2018; 24: 4846–4861.

[18] Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in Public Health. 2022; 10: 811044.

[19] Siegel RL, Miller DM, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[20] Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). Journal of Urology. 2023; 209: 1082–1090.

[21] Selvi I, Basar H. Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects. Supportive Care in Cancer. 2020; 28: 4313–4326.

[22] Velonas VM, Woo HH, dos Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. International Journal of Molecular Sciences. 2013; 14: 11034–11060.

[23] Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nature Reviews Urology. 2021; 18: 282–301.

[24] Lomas DJ, Ahmed HU. All change in the prostate cancer diagnostic pathway. Nature Reviews Clinical Oncology. 2020; 17: 372–381.

[25] Tan X, Ding XF. Research progress of anesthesia methods in prostate biopsy. Chinese Journal of Surgery. 2022; 60: 504–508. (In Chinese)

[26] Liang K, Tang CY, Ke ZJ, Zhang XJ, Huang JH. Expressions of NLRP1 and NLRC4 inflammasomes in prostate cancer and their clinical value. National Journal of Andrology. 2023; 29: 31–37. (In Chinese)

[27] Li J, Cao DH, Wei Q, Liu LR. Advances in the genetic diagnosis and treatment of prostate cancer. National Journal of Andrology. 2022; 28: 715–721. (In Chinese)

[28] Rosen RD, Sapra A. TNM classification. StatPearls Publishing: Treasure Island (FL). 2024.

[29] Das S, Dey MK, Devireddy R, Gartia MR. Biomarkers in cancer detection, diagnosis, and prognosis. Sensors. 2024; 24: 37.

[30] Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022; 27: 5730.

[31] Blas L, Shiota M, Eto M. Active surveillance in intermediate-risk prostate cancer: a review of the current data. Cancers. 2022; 14: 4161.

[32] Clinckaert A, Devos G, Roussel E, Joniau S. Risk stratification tools in prostate cancer, where do we stand? Translational Andrology and Urology. 2021; 10: 12–18.

[33] Tonry C, Finn S, Armstrong J, Pennington SR. Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. Clinical Proteomics. 2020; 17: 41.

[34] Taylor JM, Chen VE, Miller RC, Greenberger BA. The impact of prostate cancer treatment on quality of life: a narrative review with a focus on randomized data. Research and Reports in Urology. 2020; 12: 533–546.

[35] Zarrabi A, Perrin D, Kavoosi M, Sommer M, Sezen S, Mehrbod P, et al. Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies. Cancers. 2023; 15: 5269.

[36] Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Medicine. 202; 9: 20503121211034366.

[37] Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021; 2: 315–340.

[38] Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2022; 10: 1367–1401.

[39] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019; 25: 44–56.

[40] Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A survey on deep learning in medical image analysis. Medical Image Analysis. 2017; 42: 60–88.

[41] Kamel I, Ahmed MF, Sethi A. Regional anesthesia for orthopedic procedures: what orthopedic surgeons need to know. World Journal of Orthopedics. 2022; 13: 11–35.

[42] Alghandour R, Ebrahim MA, Elshal AM, Ghobrial F, Elzaafarany M, ELbaiomy MA. Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED). Urologic Oncology. 2021; 39: 831.e1–831.e10.

[43] Milosevic M, Jin Q, Singh A, Amal S. Applications of AI in multi-modal imaging for cardiovascular disease. Frontiers in Radiology. 2024; 3: 1294068.

[44] Singh A, Randive S, Breggia A, Ahmad B, Christman R, Amal S. Enhancing prostate cancer diagnosis with a novel artificial intelligence-based web application: synergizing deep learning models, multimodal data, and insights from usability study with pathologists. Cancers. 2023; 15: 5659.

[45] Tsirkas K, Zygogianni A, Kougioumtzopoulou A, Kouloulias V, Liakouli Z, Papatsoris A, et al. A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study. World Journal of Urology. 2021; 39: 1805–1813.

[46] Hsu T, Fergusson D, Stober C, Daigle K, Moledina N, Vandermeer L, et al; REaCT investigators. A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Supportive Care in Cancer. 2021; 29: 3113–3120.

[47] Gu JY, Tan MY, Ge MY, Zhai XY, Guo DD, Xu DL. Modified Shenqi Dihuang Decoction for bone metastasis of hormone-sensitive prostate cancer after castration. National Journal of Andrology. 2021; 27: 161–166. (In Chinese)

[48] Yang ZH, Xia XQ, Gao X, Yu YB, Gong RJ, Li YH. Effects of low-dose dexmedetomidine combined with hydromorphone in postoperative analgesia and on the serum IL-6 and CRP levels of prostate cancer patients. National Journal of Andrology. 2021; 27: 713–717. (In Chinese)

[49] Bhasin S, Travison TG, Pencina KM, O’Leary M, Cunningham GR, Lincoff AM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Network Open. 2023; 6: e2348692.

[50] Kato Y, Shigehara K, Kawaguchi S, Izumi K, Kadono Y, Mizokami A. Efficacy of testosterone replacement therapy on pain in hypogonadal men with chronic pain syndrome: a subanalysis of a prospective randomised controlled study in Japan (EARTH study). Andrologia. 2020; 52: e13768.

[51] Yang HJ, Kim KH, Kim DS, Lee CH, Jeon YS, Shim SR, et al. The effect of testosterone replacement on sexual function in the elderly: a systematic review and meta-analysis. World Journal of Men’s Health. 2023; 41: 861–873.

[52] Diaz P, Reddy R, Blachman-Braun R, Zucker I, Dullea A, Gonzalez DC, et al. Comparison of intratesticular testosterone between men receiving nasal, intramuscular, and subcutaneous pellet testosterone therapy: evaluation of data from two single-center randomized clinical trials. World Journal of Men’s Health. 2023; 41: 390–395.

[53] Mir N, Burke O, Yates S, Rajasekaran T, Chan J, Szmulewitz R, et al. Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global young international society of geriatric oncology drug review. Therapeutic Advances in Medical Oncology. 2023; 15: 17588359221149887.

[54] Ong S, O’Brien J, Medhurst E, Lawrentschuk N, Murphy D, Azad A. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review. Translational Andrology and Urology. 2021; 10: 3918–3930.

[55] Bhasin S, Travison TG, Pencina KM, O’Leary M, Cunningham GR, Lincoff AM, et al. JAMA Netw Open. 2023; 6: e2348692.

[56] Gregucci F, Carbonara R, Surgo A, Ciliberti MP, Curci D, Ciocia A, et al. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial. Radiologia Medica. 2023; 128: 501–508.

[57] Nguyen EK, Quan K, Parpia S, Tran S, Swaminath A. Stereotactic body radiotherapy for osseous low alpha-beta resistant metastases for pain relief-SOLAR-P. Radiation Oncology. 2021; 16: 170.

[58] Andriole GL, Scarsbrook AF, Savir-Baruch B. LOCATE/FALCON study groups. impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials. Urologic Oncology. 2023; 41: 293.e1–293.e7.

[59] Ghai S, Finelli A, Corr K, Chan R, Jokhu S, Li X, et al. MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase II trial. Radiology. 2021; 298: 695–703.

[60] Zapatero A, Álvarez A, Guerrero A, Maldonado X, González San Segundo C, Cabeza MA, et al. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: results from a phase III trial. Radiotherapy and Oncology. 2021; 160: 115–119.

[61] Rowe LS, Harmon S, Horn A, Shankavaram U, Roy S, Ning H, et al. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques. Radiotherapy and Oncology. 2021; 16: 32.

[62] Cetin T, Yalcin MY, Karaca E, Ozbilen MH, Ergani B, Koc G, et al. Laparoscopic surgery experience does not influence oncological and functional results of robotic-assisted laparoscopic prostatectomy. Urologia. 2022; 89: 240–243.

[63] Su SH, Chang YH, Huang LK, Chu YC, Kan HC, Liu CY, et al. Clinical predictors for biochemical failure in patients with positive surgical margin after robotic-assisted radical prostatectomy. Tumori. 2022; 108: 270–277.

[64] Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine. 2023; 388: 1547–1558.

[65] Liu J, Li WP, Yang SJ. Updated studies on the immunotherapy of prostate cancer. National Journal of Andrology. 2022; 28: 349–355. (In Chinese)

[66] Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. European Urology. 2021; 79: 263–282.

[67] van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. The American Journal of Surgical Pathology. 2020; 44: e87–e99.

[68] Tisseverasinghe S, Bahoric B, Anidjar M, Probst S, Niazi T. Advances in PARP inhibitors for prostate cancer. Cancers. 2023; 15: 1849.

[69] Nambiar DK, Mishra D, Singh RP. Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials. Oncology Research. 2023; 31: 405–421.

[70] Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Current Oncology Reports. 2021; 23: 15.

[71] Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, et al. Molecular events in neuroendocrine prostate cancer development. Nature Reviews Urology. 2021; 18: 581–596.

[72] Xie Y, Ning S, Hu J. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression. Journal of Cancer Research and Clinical Oncology. 2022; 148: 1813–1823.

[73] Zamora I, Freeman MR, Encío IJ, Rotinen M. Targeting key players of neuroendocrine differentiation in prostate cancer. International Journal of Molecular Sciences. 2023; 24: 13673.

[74] Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature Clinical Practice Urology. 2009; 6: 76–85.

[75] Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. The New England Journal of Medicine. 2004; 351: 1488–1490.

[76] Shahinozzaman M, Islam M, Basak B, Sultana A, Emran R, Ashrafizadeh M, et al. A review on chemistry, source and therapeutic potential of lambertianic acid. Journal of Biosciences. 2021; 76: 347–356.

[77] Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI. Targeting PI3K/AKT signaling pathway in obesity. Biomedicine & Pharmacotherapy. 2023; 159: 114244.

[78] Pérez-Cremades D, Bueno-Betí C, García-Giménez JL, Ibañez-Cabellos JS, Pallardó FV, Hermenegildo C, et al. Extracellular histones trigger oxidative stress-dependent induction of the NF-kB/CAM pathway via TLR4 in endothelial cells. Journal of Physiology and Biochemistry. 2023; 79: 251–260.

[79] Li YJ, Zhang C, Martincuks A, Herrmann A, Yu H. STAT proteins in cancer: orchestration of metabolism. Nature Reviews Cancer. 2023; 23: 115–134.

[80] Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, Philippe J, Mirzaei H, et al. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: challenges and prospects. Acta Pharmaceutica Sinica B. 2021; 11: 1721–1739.

[81] Yang J, Aljitawi O, Van Veldhuizen P. Prostate cancer stem cells: the role of CD133. Cancers. 2022; 14: 5448.

[82] Gogola S, Rejzer M, Bahmad HF, Alloush F, Omarzai Y, Poppiti R. Anti-cancer stem-cell-targeted therapies in prostate cancer. Cancers. 2023; 15: 1621.

[83] Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunology Research. 2015; 3: 483–494.

[84] Wolf P, Alzubi J, Gratzke C, Cathomen T. The potential of CAR T cell therapy for prostate cancer. Nature Reviews Urology. 2021; 18: 556–571.

[85] Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo ASY, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate. 2016; 76: 1257–1270.

[86] Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A. Microbiome and cancers, with focus on genitourinary tumors. Frontiers in Oncology. 2019; 9: 178.

[87] Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-Negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Molecular Therapy. 2018; 26: 1855–1866.

[88] Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S, et al. PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model. Molecular Therapy Oncology. 2020; 18: 226–235.

[89] Lin M, Sun X, Lv L. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer. Molecular Therapy Oncology. 2023; 29: 91–106.

[90] Gabrielli G, Shouval R, Ghilardi G, van den Brink M, Ruella M. Harnessing the gut microbiota to potentiate the efficacy of CAR T cell therapy. Hemasphere. 2023; 7: e950.

[91] Fu C, Yang Z, Yu J, Wei M. The interaction between gut microbiome and anti-tumor drug therapy. American Journal of Cancer Research. 2021; 11: 5812–5832.

[92] Riscado M, Baptista B, Sousa F. New RNA-based breakthroughs in Alzheimer’s disease diagnosis and therapeutics. Pharmaceutics. 2021; 13: 1397.

[93] Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacology & Therapeutics. 2021; 221: 107753.

[94] Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Frontiers in Oncology. 2023; 13: 1170264.

[95] Zhou X, Ni Y, Liang X, Lin Y, An B, He X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Frontiers in Immunology. 202; 13: 915094.

[96] Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, et al. Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects. Clinical Medicine Insights: Oncology. 2021; 15: 11795549211035540.